Harry Boxer
The Technical Trader
The stock market indices had a tough session to start the week. It was a down day, for sure. The day opened down, they pulled back, popped, couldn’t get through the highs, and sold off to the morning lows and session lows by about 11-11:15 this morning. They then rallied midday, and could not get through the highs, rolled over, retested twice, but couldn’t break down as well. Enough damage had been done to create losses for the day.
Net on the day, the Dow was down 55.75 at 17,737.00. The S&P 500 was down 6.65 to 2066.13. The Nasdaq 100 was down 20.38 to 4511.70.
Advance-declines were nearly 3 to 1 negative on the New York Stock Exchange, and 3 to 2 negative on the Nasdaq. Up/down volume was 2 1/2 to 1 negative on New York, total volume of 3 1/2 billion shares traded. The Nasdaq traded 1 2/3 billion shares and had a 5 to 3 negative volume ratio.
TheTechTrader.com board was a mixed picture today. Priceline Inc. (PCLN) was down 17.94 to 1281.76, Google Inc. (GOOG) down 4.62 to 745.29, Amazon.com Inc. (AMZN) down 5.31 to 593.19, and Netflix, Inc. (NFLX) down 1.35 to 104.35. However, Apple gained 1.13 to 111.12.
Baidu, Inc. (BIDU) lost 1.36 to 188.97, Facebook, Inc. (FB) gave back 3.51 to 112.55, and First Solar, Inc. (FSLR) was down just 24 cents to 67.24.
Tesla Motors, Inc. (TSLA) jumped 9.40 to 246.90, after figures were released for the new model sales.
Other stocks of note to the upside included Stratasys Ltd. (SSYS), a new swing trade for us, up 2.25 to 27.65, Editas Medicine Inc. (EDIT) up 2.68 to 39.58, Bristol-Myers Squibb Company (BMY) 1.06 to 65.97, and ACADIA Pharmaceuticals Inc. (ACAD) 1.40 to 30.06, after reaching as high as 31.79.
The Direxion Daily S&P Biotech Bull 3X ETF (LABU) ran 1.00 to 30.97.
Checking the TheTechTrader.com percent-gain leaderboard, Sky440, Inc. (SKYF) was up 1.64 to 5.90, or 38 1/2%, on 18 million shares. Sorrento Therapeutics, Inc. (SRNE) climbed 85 cents to 6.30, or 16%, on over a half million shares. Genocea Biosciences, Inc. (GNCA) bounced 88 cents to 6.83, or 15%, on 4.8 million shares. Celldex Therapeutics, Inc. (CLDX) popped 42 cents to 4.37, or 11%, on 5.1 million shares.
OncoCyte Corporation (OCX) led the way today, up 1.85 to 6.07, or 44%, on low volume. MediciNova Inc. (MNOV) advanced 1.10 to 9.00, or 14%. NantKwest, Inc. (NK) climbed 1.09 to 9.72, or 13%.
Flexion Therapeutics, Inc. (FLXN) ran 1.53 to 10.95, or 16%, on over a half million shares. Momo Inc. (MOMO) had an interesting day, up 1.26 to 12.19, or 11 1/2%, on 4 million shares. Esperion Therapeutics, Inc. (ESPR) thrust 1.86 to 19.36, or 11%.
Edwards Lifesciences Corp. (EW) was big on big earnings, up 15.16 to 105.08, or 17%, on 9 million shares.
Stepping back and reviewing the hourly chart patterns, the indices were down in the morning, up midday, back down in the afternoon, couldn’t rally enough to take back the losses, and ended the day with a weak start to the week.
Let’s see what happens tomorrow.
Good Trading!
In using any portion of The Technical Trader, you agree to the Terms and Conditions governing the use of the service as described in this disclaimer. Our disclaimers, policies and terms are subject to change without notice. The Technical Trader (www.thetechtrader.com) is published by Century-Pacific Investments and AdviceTrade, Inc., both of which are publishers. The Web site is maintained by Codexia, LLC. None of these firms, nor Mr. Boxer, is registered as a broker-dealer or investment adviser either with the U.S. Securities and Exchange Commission or with any state securities authority. Each trade mentioned in the diary and other sections of The Technical Trader is hypothetical and is not an actual trade. Mr. Boxer and employees of Century-Pacific, AdviceTrade and Codexia are not allowed to have personal positions in stocks mentioned in the diary and other sections of The Technical Trader. This policy, first announced to subscribers on June 2, 2004, gave Mr. Boxer a deadline that was extended to July 30, 2004 for liquidating any existing personal holdings in stocks mentioned on the site. Our holdings page, in which Mr. Boxer listed his personal positions in stocks mentioned on the site, was removed at that time. The publishers are not permitted to have any financial relationship with companies mentioned on the site. Mr. Boxer may recommend trades of stocks mentioned in the Diary as a consultant to hedge funds, but has agreed not to make such recommendations until after the stock has been posted on The Technical Trader Web site. Mr. Boxer's commentaries, trading ideas and model trades represent his own opinions and should not be relied upon for purposes of effecting securities transactions or other investing strategies, nor should they be construed as an offer or solicitation of an offer to sell or buy any security. You should not interpret Mr. Boxer's opinions as constituting investment advice. Neither we nor Mr. Boxer claim to have any non-public information regarding the companies mentioned in this site. The trade prices that appear on this Web site are based on the average of the real-time bid and real-time ask prices provided by Money.net, except when entered manually by Mr. Boxer should Money.net's feed be temporarily down. There may be a delay between the price as it appears in the diary and the current price that you see from your terminal due to delays in Internet connectivity, quote delays, refresh intervals in the case of the Web-based diary page, data entry errors, and market conditions, and also due to times when Mr. Boxer is not available to make the trade at the moment a previously stated target has been met. Entries may at times be in error due to system or data-entry errors. Hypothetical performance results do not include trading commissions and other execution costs that would be incurred if the trades referenced in the diary or elsewhere on the site were actual trades. Past performance is no guarantee of future results.
Recommended Content
Editors’ Picks
EUR/USD clings to gains above 1.0750 after US data
EUR/USD manages to hold in positive territory above 1.0750 despite retreating from the fresh multi-week high it set above 1.0800 earlier in the day. The US Dollar struggles to find demand following the weaker-than-expected NFP data.
GBP/USD declines below 1.2550 following NFP-inspired upsurge
GBP/USD struggles to preserve its bullish momentum and trades below 1.2550 in the American session. Earlier in the day, the disappointing April jobs report from the US triggered a USD selloff and allowed the pair to reach multi-week highs above 1.2600.
Gold struggles to hold above $2,300 despite falling US yields
Gold stays on the back foot below $2,300 in the American session on Friday. The benchmark 10-year US Treasury bond yield stays in negative territory below 4.6% after weak US data but the improving risk mood doesn't allow XAU/USD to gain traction.
Bitcoin Weekly Forecast: Should you buy BTC here? Premium
Bitcoin (BTC) price shows signs of a potential reversal but lacks confirmation, which has divided the investor community into two – those who are buying the dips and those who are expecting a further correction.
Week ahead – BoE and RBA decisions headline a calm week
Bank of England meets on Thursday, unlikely to signal rate cuts. Reserve Bank of Australia could maintain a higher-for-longer stance. Elsewhere, Bank of Japan releases summary of opinions.